ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.62
0.96%
US Tech 100
18,064.80
0.02%
S&P 500
5,277.51
0.80%
US Dollar vs CAD
1.36525
-0.01%
Bitcoin
67,682.99
0.30%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. InflaRx NV (IFRX)

  7. InflaRx NV (IFRX) News

IFRX

InflaRx NV (IFRX)

InflaRx NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IFRX
DateTimeSourceHeadlineSymbolCompany
05/21/20243:15PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
05/21/20241:30PMGlobeNewswire Inc.InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other ImmunomodulatorsNASDAQ:IFRXInflaRx NV
05/08/20247:43AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
05/08/20246:30AMGlobeNewswire Inc.InflaRx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
04/30/20246:30AMGlobeNewswire Inc.InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024NASDAQ:IFRXInflaRx NV
04/24/20246:30AMGlobeNewswire Inc.InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters EventNASDAQ:IFRXInflaRx NV
03/21/20246:00AMGlobeNewswire Inc.InflaRx Reports Full Year 2023 Results and Announces INF904 Development PlansNASDAQ:IFRXInflaRx NV
03/19/20246:30AMGlobeNewswire Inc.InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024NASDAQ:IFRXInflaRx NV
02/22/20246:30AMGlobeNewswire Inc.InflaRx Appoints Jan Medina as Head of Investor RelationsNASDAQ:IFRXInflaRx NV
01/25/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
01/25/20246:30AMGlobeNewswire Inc.InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible PatientsNASDAQ:IFRXInflaRx NV
01/04/20243:16PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
01/04/20246:00AMGlobeNewswire Inc.InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904NASDAQ:IFRXInflaRx NV
11/06/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
11/06/20236:30AMGlobeNewswire Inc.InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumNASDAQ:IFRXInflaRx NV
11/01/20237:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
11/01/20236:30AMGlobeNewswire Inc.InflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
09/11/20237:45AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
09/11/20236:00AMGlobeNewswire Inc.InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904NASDAQ:IFRXInflaRx NV
08/30/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
08/30/20236:30AMGlobeNewswire Inc.InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)NASDAQ:IFRXInflaRx NV
08/10/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
08/10/20236:30AMGlobeNewswire Inc.InflaRx Reports Second Quarter 2023 Financial Results & Operating UpdateNASDAQ:IFRXInflaRx NV
07/12/20233:01PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IFRXInflaRx NV
07/11/202311:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IFRXInflaRx NV
06/30/20233:06PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:IFRXInflaRx NV
06/28/20237:31AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IFRXInflaRx NV
06/28/20237:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
06/28/20236:30AMGlobeNewswire Inc.InflaRx Appoints Dr. Camilla Chong as Chief Medical OfficerNASDAQ:IFRXInflaRx NV
06/21/20237:30AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IFRXInflaRx NV
 Showing the most relevant articles for your search:NASDAQ:IFRX

Your Recent History

AMEX
BUFG
FT Vest Buffered Allocat...
BIT
NSCITA3K4DV1
European Union
TSX
RBNK
RBC Canadian Bank Yield ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved